Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lisdexamfetamine is a central nervous system stimulant and a prodrug of dextroamphetamine. It is primarily used to treat attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 years and older, as well as moderate to severe binge eating disorder (BED) in adults[1][2][5]. After oral administration, lisdexamfetamine is converted by red blood cells into its active form, dextroamphetamine. Dextroamphetamine increases the availability of dopamine and norepinephrine in the brain by blocking their reuptake and promoting their release from presynaptic neurons[3][5]. Lisdexamfetamine was developed to provide a longer duration of action with reduced abuse potential compared to other amphetamines[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lisdexamfetamine.